DRUG · Unmapped registry intervention
Felmetatug Vedotin
Find medicine records ·
Find other trials using this name
Clinical trial
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
NCT05194072
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Pembrolizumab
Normalized identity: pembrolizumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedA Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Ovarian Neoplasmsunresolved
Peritoneal Neoplasmsunresolved
Fallopian Tube Neoplasmsunresolved
Triple Negative Breast Neoplasmsunresolved
HER2 Negative Breast Neoplasmsunresolved
Endometrial Neoplasmsunresolved
Cholangiocarcinomaverified · MONDO: cholangiocarcinoma
Interventions
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Seagen, a wholly owned subsidiary of Pfizerlead sponsor
Mapped research locations
AuroraColorado, United States4IndianapolisIndiana, United States3HoustonTexas, United States2ChicagoIllinois, United States2NashvilleTennessee, United States2OrlandoFlorida, United States2San AntonioTexas, United States1MadridSpain1BarcelonaSpain1LondonUnited Kingdom1BerlinGermany1JacksonvilleFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05194072 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.